EPHB2

Across TCGA pan-cancer cohorts, EPHB2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EPHB2 data layer compared with 31 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher EPHB2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EPHB2 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

ACC, STAD, and DLBC are the cancer types where EPHB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.110	0.673	.001	20	view →
STAD	OS	Median	II,III,IV	0.111	0.711	<.001	15	view →
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	12	view →
HNSC	DFS	Median	IV	0.122	0.670	.008	9	view →
SCLC	DFS	Median	II,III,IV	1.000	0.304	.029	7	view →
LGG	OS	Median	All	0.324	0.799	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EPHB2–ACC (DFS)

Open the ACC breakdown →